RFS Pharma, LLC, today announced the receipt of an R01 grant from the National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (NIH) in association with a collaborative academic institution. RFS Pharma will receive US$525,000 as part of this grant and the principal objective will be to evaluate natural products isolated from plants, bacteria and fungi against viral hepatitis infections. The extracts that demonstrate excellent activity and no toxicity will be further isolated and characterized at the molecular level.
As part of this collaboration, RFS Pharma will test more than 5,000 natural products from the National Cancer Institute (NCI) repository.
“We are honored, that in this highly competitive environment, we were coawarded a prestigious five-year R01 grant based on our experience in antiviral drug discovery,” said Dr. Raymond F. Schinazi, Founder and Chairman of the Board of Directors at RFS Pharma. “Using our in-depth testing program, we anticipate that this collaborative effort will lead to successful development and identification of several lead antiviral plant and microbe based products”. Natural products are a highly productive resource for the discovery and development of new, innovative treatments providing unique classes of compounds with novel structural features and mechanisms of action.